Navigation Links
New Oral Rinse For Gingivitis Approved By FDA

The Food and Drug Administration (FDA) has recently approved of a new prescription treatment for gingivitis, a common // gum disease that affects almost everybody. Gingivitis is an inflammation of the gums haracterized as swollen, red, or bleeding gums. It is believed that plaque-forming bacteria that live in the mouth and on the tooth surfaces are a cause of gingivitis and substances released by the bacteria cause the gum inflammation. Reduction in the inflammation associated with gingivitis can be effectively achieved by reducing the number of plaque bacteria.

The Decapinol Oral Rinse thus works against gingivitis by reducing the number of bacteria that attach to tooth surfaces and cause dental plaque. Decapinol contains a substance called a surfactant that acts as a physical barrier, making it harder for bacteria to stick to tooth surfaces. However it is only approved for use in persons 12 years of age or older when routine oral hygiene is not adequate to prevent gingivitis and is contraindicated in pregnant women.

In a comparison study conducted in adults with mild to severe gingivitis the use of Decapinol was compared either to "no treatment" or to an antimicrobial rinse. The results of the study showed that Decapinol decreased gingivitis up to 60%--compared to no treatment. Although it has proven benefits Decapinol Oral Rinse is being regulated only as a medical device and not as a drug because its primary mode of action is to create a physical barrier, rather than to act chemically.
'"/>




Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New FDA Approved Drug NATRECOR For Heart Failure Patients
4. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
5. AIDS Generic Drugs Approved by FDA for Sale in US
6. FDA Approved Nerve-Stimulation Therapy Now Available In New York
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... Urologix, the market leader for in-office minimally ... Hyperplasia (BPH), announces new private ownership and is operating ... device industry veteran of more than 20 years, has ... Plymouth, Minn. The company,s ... Prostiva® RF Therapy, will continue to be broadly available ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology: